Abstract
The present study aimed to investigate the associations between high-density lipoprotein (HDL) functionality and major adverse cardiovascular events (MACE) in patients who have undergone coronary computed tomography angiography (CCTA). We performed a prospective cohort study and enrolled 151 patients who underwent CCTA and had a follow-up of up to 5 years. We measured cholesterol efflux capacity (CEC), caspase-3/7 activity and monocyte chemoattractant protein-1 (MCP-1) secretion as bioassays of HDL functionality. The patients were divided into MACE(−) (n = 138) and MACE(+) (n = 13) groups. While there was no significant difference in %CEC, caspase-3/7 activity or MCP-1 secretion between the MACE(−) and MACE(+) groups, total CEC and HDL cholesterol (HDL-C) in the MACE(+) group were significantly lower than those in the MACE(−) group. Total CEC was correlated with HDL-C. A receiver-operating characteristic curve analysis showed that there was no significant difference between the areas under the curves for total CEC and HDL-C. In conclusion, total CEC in addition to HDL-C, but not %CEC, was associated with the presence of MACE. On the other hand, HDL functionality with regard to anti-inflammatory and anti-apoptosis effects was not associated with MACE.
Highlights
In patients who are treated for atherosclerotic cardiovascular disease (ASCVD), there is a possibility of some residual risks even when the low-density lipoprotein cholesterol (LDL-C) level has been significantly reduced [1,2]
There were no significant differences in other factors, including %coronary artery disease (CAD), the number of VD, Gensini score, left ventricular ejection fraction (LVEF), %chronic kidney disease (CKD), estimated glomerular filtration rate (eGFR) and medications between the major adverse cardiovascular events (MACE)(+) and MACE(−) groups
high-density lipoprotein (HDL) functionality with regard to anti-inflammatory and anti-apoptosis effects was not associated with MACE
Summary
In patients who are treated for atherosclerotic cardiovascular disease (ASCVD), there is a possibility of some residual risks even when the low-density lipoprotein cholesterol (LDL-C) level has been significantly reduced [1,2]. Such residual risks include high levels of the triglyceride (TG), a low level of high-density lipoprotein cholesterol (HDL-C) and other uncontrolled risk factors [1,2,3,4,5,6]. A recent study in a Japanese cohort indicated that extremely high HDL-C (≥90 mg/dL) had an adverse effect on ASCVD mortality [7]. HDL functionality is a critical residual risk factor for ASCVD
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
